Actively Recruiting
Evaluation of CYTALUX pafolacianine Injection with Near-Infrared Imaging for Detecting Gastrointestinal Adenocarcinomas During Surgery
Led by Cedars-Sinai Medical Center · Updated on 2026-11-02
15
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of CYTALUX pafolacianine injection combined with near-infrared NIR fluorescent imaging to detect types of adenocarcinoma including gastric, esophageal, and appendiceal cancers. This open-label Phase 4 study aims to determine the feasibility of this imaging method during surgery for gastrointestinal malignancies. The study focuses on adults with a diagnosis or strong suspicion of these cancers who require surgical intervention. Participants will receive a dose of 0.025 mgkg of CYTALUX injected intravenously over an hour. The infusion is completed between 1 to 24 hours before the planned surgery. During surgery, the tumors scheduled for removal will be assessed using NIR imaging both while operating and afterward on the back table. This approach is combined with standard care surgery procedures. During the study, participants will undergo surgery with the imaging procedure to evaluate tumor detection. Researchers will measure the feasibility of using CYTALUX with NIR imaging over a 12-month period and count the number of lesions detected. Safety monitoring and follow-up will continue throughout the study duration, which is expected to complete by September 2027. Participants must also agree to stop folate supplements 48 hours prior to receiving the injection and provide informed consent.
CONDITIONS
Brief Title
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
Research Team
L
Laura Sarmiento
A
Arman Jordan
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here